TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Kidney Awareness Registry and Education Study
Brief Summary: The purpose of this study is to evaluate the feasibility and acceptability of two different interventions aimed at improving health outcomes among patients with chronic kidney disease (CKD), who are at high risk of CKD progression. Specifically, this study will examine how best to implement a provider-level intervention (access to a CKD-registry) and a patient-oriented intervention (automated telephone self-management (ATSM) + health coach) on patient health outcomes, with a 2x2 factorial design.


Options:
A: Inclusion Criteria:

* African American race
* male or female
* 21 to 80 years old
* diagnosis of ESRD
* eligible for listing on the kidney transplant waiting list at Beth Israel Deaconess Medical Center
* resides within 150 minutes of transplant center
* residential or cell phone service
* signed informed consent

Exclusion Criteria:

* Wait-listed for additional organ transplant (i.e., heart, liver)
* current substance abuse or dependency
* known or suspected psychotic disorder
* known or suspected mental retardation
B: Inclusion Criteria:

* Persons \> 21 years of age
* first time recipient of a solitary kidney transplant
* prescribed at least 3 medications for immunosuppression and hypertension
* previous history of non-adherence
* functioning kidney transplant
* ability to speak, hear and understand English
* able to use medication delivery device and self administer medications
* able to operate blood pressure monitor
* comfortable using cell phone
* no other diagnosis that might shorten lifespan
* transplant physician's assent that the patient can participate

Exclusion Criteria:

* failure to meet all inclusion criteria
C: Inclusion Criteria:

* renal transplant recipient
* at least 21 years of age
* receive an immunosuppressant regimen that contains oral cyclosporine or tacrolimus
* be at least one year post-transplant
* obtain immunosuppressant therapy from Avella Specialty Pharmacy for at least one year prior to study enrollment and during the study period

Exclusion Criteria:

* pregnant
* prisoner
* institutionalized
* unable to give informed consent
D: Inclusion Criteria:

* Patients with CKD (defined as estimated Glomerular Filtration Rate \< 60ml/min/1.73m2 or proteinuria consistently over 3 months) who speak English, Spanish or Cantonese and have a primary care provider

Exclusion Criteria:

* Kidney transplant recipients; pregnant women; individuals with an eGFR \<15 ml/min/1.73 m2; prevalent dementia; impaired cognition or severe mental illness; expected life expectancy \<6 months; no phone access; self-reported hearing impairment; severe visual impairment preventing use of a touch-tone telephone keypad; and non-study language

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Role Of Lactobacillus Reuteri in Preventing Necrotizing Enterocolitis in Very Low Birth Weight Infants
Brief Summary: Probiotics are favorable microorganisms that regulate the flora of the gastrointestinal system and stimulate the immune system. Necrotizing enterocolitis incidence is 10-25% in newborn infants whose birth weights are \< 1500 g. Although bifidobacterium and other lactobacilli spp. have been used to reduce the incidence of necrotizing enterocolitis in clinical trials, Lactobacillus reuteri has not been used in the prevention of necrotizing enterocolitis in very low birth weight infants yet. The objective of this study is to evaluate the efficacy of orally administered Lactobacillus reuteri in reducing the incidence and severity of necrotizing enterocolitis in very low birth weight infants.


Options:
A: Inclusion Criteria:

* Preterm VLBW infants (birth weight \< 1500 gm) who are enterally fed are eligible for the trial.

Exclusion Criteria:

* Preterm VLBW infants who have severe asphyxia (stage III), fetal chromosome anomalies, fetal cyanotic congenital heart disease, congenital intestine atresia, gastroschisis and omphalocele are excluded.
B: Inclusion Criteria:

* Very low birth weight infants \< 1500 gr
* Gestational age \< 32 weeks

Exclusion Criteria:

* Genetic anomalies
* Short bowel syndrome
* Not willing to participate
* Allergy to Lactobacillus reuteri components
C: Inclusion Criteria:

* Admission to the NICU
* Written parental consent
* Birth weight \< 2000 grams
* Hemodynamically stable
* \< 48 hours of age

Exclusion Criteria:

* Evidence or suspicion of congenital intestinal obstruction or perforation
* Prenatal or postnatal diagnosis of gastroschisis, large omphalocele, or congenital diaphragmatic hernia
* Major congenital heart defects
* Anticipated transfer to a NICU not involved in the study
D: Inclusion Criteria:

* Pregnant women from families with at least one family member having an allergic disease

Exclusion Criteria:

* Women presenting severe immunological or other chronic diseases (rheumatoid arthritis, diabetes, inflammatory bowel disease, thyroid diseases, malignancies etc.)
* Women who cannot be expected to comply with treatment
* Women currently participating or having participated in other clinical trial during the last 2 months prior to the beginning of the intervention.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Risk Factors of Difficult Intubation and Related Complications in Adults in Intensive Care Units(ICU)
Brief Summary: Difficult intubation is challenging in intensive care units. There are limited data regarding risk factors of difficult intubation in ICU. The primary purpose of the investigators study is to assess the risk factors of difficult airway in adults in ICU.


Options:
A: Inclusion Criteria:

* age \> 18years
* elective surgery
* single lumen endotracheal intubation required
* signed informed consent
* one risk factor for a difficult laryngoscopy ( Mallampati score \>3, inter-incisor gap \< 3.5cm, thyromental distance \< 6.5cm, sternomental distance \< 12.5cm, reduced neck extension and flexion)

Exclusion Criteria:

* lack of patient consent
* anesthesiologist declines to consent
* contraindication to neuromuscular blockade
* ASA 4
* rapid sequence intubation
* previous failed intubation
* other method of intubation indicated eg fiberoptic intubation, awake tracheostomy
* symptomatic gastro-esophageal reflux
* cervical spine instability
* unstable hypertension and symptomatic coronary artery disease
* cerebrovascular disease or raised intracranial pressure
* oral/pharyngeal/laryngeal carcinoma
* loose teeth/poor dentition
B: Inclusion Criteria:

* More or equal to 18 years old
* Men and women
* Informed patient
* Affiliated or benefit from an disease insurance
* Available for a 28 days follow-up
* Intubated patients in Intensive Care Unit

Exclusion Criteria:

* Law protected patients
* Opposed to participate to study
C: Inclusion Criteria:

* After signing of the informed consent,
* ASA physical status I and II
* Mallampati class 1\& 2,
* BMI \< 35,
* Undergoing elective surgical procedures (not exceeding two hours in duration) requiring ET intubation

Exclusion Criteria:

* Patients undergoing day case,
* bariatric, cardiac, nasal, oral or head \& neck surgeries,
* requiring placement of throat pack or nasogastric/ orogastric tube,
* patients assigned to rapid sequence induction,
* hoarseness,
* patients with anticipated difficult intubation,
* history of recent upper respiratory tract infection,
* history of difficult intubation
* psychiatric disorders hindering proper evaluation,
* use of steroids (oral or inhalational) or non-steroidal anti-inflammatory drugs within one week of surgery or previous surgery within last two weeks
D: Inclusion Criteria:

* patient scheduled for a general anesthesia with orotracheal intubation

Exclusion Criteria:

* predictable risk of difficult mask ventilation or of difficult tracheal intubation
* necessity of a rapid sequence induction
* contra-indication to the use of the automated administration of propofol and of remifentanil
* contra-indication to the use of atracurium
* Otolaryngology, thoracic surgery, or intracranial surgery

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Study of Perineal Protection Device
Brief Summary: Objective:

To investigate the protective effects of a newly invented device for reducing tears in the perineum during vaginal childbirth.

Design:

A multicenter randomized control trial performed at three hospitals in Sweden, in Helsingborg, Lund and Malmö. Participants recruited are women with vaginal delivery (N=1200), cephalic presentation. They will be randomized to an intervention group, with a perineal protection device, and a control group deliver as normal.

Main outcome measures:

The effect on the frequency and extension of perineal ruptures grade I, II and anal sphincter rupture are measured.


Options:
A: Inclusion Criteria:

* nullipara
* primipara with previous cesarean section

Exclusion Criteria:

* Multipara
* Twin pregnancies
* Nullipara with elective cesarean section
* Preterm delivery before 35 gestational weeks
* Breech delivery
* Acute cesarean section
B: Inclusion Criteria:

* Women with singleton pregnancy and a fetus in cephalic presentation
* admitted for labor
* rupture of the membranes or induction after 37 completed gestational weeks
* and reaching full cervical dilatation.

Exclusion Criteria:

* Operative delivery
C: Inclusion Criteria:

* Vaginal delivery

Exclusion Criteria:

* Age below 18 years and no understanding of written and oral information.
D: Inclusion Criteria:

* With no pregnancy-related complications diagnosed during pregnancy,
* No definitive indication for C-section,
* Satisfying the pregnancy week in terms of the fetal dimensions,
* At the 37th-42nd gestation week,
* Applying to have her first or second birth,
* With no systemic condition,
* With head presentation,
* At the latent phase of the first stage of birth with a dilatation under 4 cm and effacement below 50%,
* That have provided written consent specifying their voluntariness in participating in the study.

Exclusion Criteria:

* With pregnancy-related complications diagnosed during pregnancy,
* Definitive indication for C-section,
* No satisfying the pregnancy week in terms of the fetal dimensions,
* At the \<37th- \>42nd gestation week,
* With systemic condition,
* With no head presentation,
* At the latent phase of the first stage of birth with a dilatation above 4 cm
* No have provided written consent specifying their voluntariness in participating in the study.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Study of Perineal Protection Device
Brief Summary: Objective:

To investigate the protective effects of a newly invented device for reducing tears in the perineum during vaginal childbirth.

Design:

A multicenter randomized control trial performed at three hospitals in Sweden, in Helsingborg, Lund and Malmö. Participants recruited are women with vaginal delivery (N=1200), cephalic presentation. They will be randomized to an intervention group, with a perineal protection device, and a control group deliver as normal.

Main outcome measures:

The effect on the frequency and extension of perineal ruptures grade I, II and anal sphincter rupture are measured.


Options:
A: Inclusion Criteria:

* Women with singleton pregnancy and a fetus in cephalic presentation
* admitted for labor
* rupture of the membranes or induction after 37 completed gestational weeks
* and reaching full cervical dilatation.

Exclusion Criteria:

* Operative delivery
B: Inclusion Criteria:

* Low risk patients in active labor admitted to the IMIP; Gestational age between 37 and 42 weeks;
* Cephalic fetus;
* Cervical dilatation up to 8 cm at the time of inclusion in the study.

Exclusion Criteria:

* Indication of cesarean section at the time of the approach;
* Inability to understand and / or perform vocalization maneuvers.
* Patients with Dysphonia
* Deaf and mute patients
* Use of Oxytocin prior to randomization
C: Inclusion Criteria:

* Singleton gestations
* Low risk pregnancies
* 37 to 42 weeks of gestations

Exclusion Criteria:

* Multiple gestations
* Preterm birth
D: Inclusion Criteria:

* Vaginal delivery

Exclusion Criteria:

* Age below 18 years and no understanding of written and oral information.

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Community Based Management of Fast Breathing in Infants Aged < 60 Days: A Double-Blind, Randomized Placebo-Controlled Trial in Low-income Settlements of Karachi
Brief Summary: The aim of the study is to determine optimal management of isolated fast breathing in young infants in a trial design conducted in primary care settings.

The investigators hypothesized that proportion of infants who fail therapy will be 4% in each group. A 6% or less difference in failure rate will be considered equivalent.


Options:
A: Inclusion Criteria:

* Live born infants from all pregnancies within participating villages will be eligible for enrollment in this study.

Exclusion Criteria:

* Child born with congenital malformation
* Serious birth injury
* Neonates with birth asphyxia and serious infections
* Gestational age less than 32 weeks
* Birth weight less than 1500 gms
* Refusal by parents to participate
B: Inclusion Criteria

* Young infant (0-59 days of age)
* Fast breathing i.e., respiratory rate ≥60 breaths/min
* O2 Saturation ≥90%
* Resident of catchment area (to ensure complaint and follow up)
* Refused hospitalization and investigations
* Informed consent is provided by a parent (or legal guardian).

Exclusion Criteria:

* Preterm infants (born \<37 weeks)
* Presence of audible murmur
* Any concurrent signs of severe infection:
* not feeding well
* movement only when stimulated
* severe chest in-drawing
* axillary temperature ≥38.0oC or ≤35.5oC
* Any sign of being critically ill (Cyanosis, bulging fontanel, unable to feed, unable to cry, apnoea, convulsions, unconscious, persistent vomiting)
* Weight \<1800gm at the time of presentation
* Major congenital malformations or suspected chromosomal abnormalities
* Hospitalization for illness in the last two weeks
* Previous inclusion in the study
C: Inclusion Criteria:

* Children under five (\< or =59 months)

Exclusion Criteria:

* Children over five years (\> 59 Months)
D: Inclusion Criteria:

* living in one of the study cluster (villages)
* no story of allergy to any of the study drugs
* history of fever or body temperature \>= 38.5°C

Exclusion Criteria:

* signs of severity/complications like impaired consciousness, convulsions, fast breathing etc

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Self-administered Intravaginal 2% Lidocaine Gel Prior to Intrauterine Device Insertion in Nulliparous Women: a Randomized Controlled Trial
Brief Summary: This study is designed to evaluate if self-inserted intravaginal 2% lidocaine gel is effective at decreasing pain during intrauterine device insertion in nulliparous women.


Options:
A: Inclusion Criteria:

- nulliparous women with no previous history of IUD use

Exclusion Criteria:

* malformation of uterus
* myomas
* acute gynecological infection
* malignant uterine or cervical tumor

In addition if requesting a Cu-IUD

* heavy menstruations
* iron deficiency
* bleeding disorder
* copper allergy or Wilson's disease
B: Inclusion Criteria:

* patients who wanted to use the LNG-IUS as a contraceptive
* age between 18 and 45 years
* nulliparity
* absence of previous vaginal delivery

Exclusion Criteria:

* women in categories 3 and/or 4 for LNG-IUS use according to the medical eligibility criteria of the World Health Organization
* illicit drug and/or alcohol users
* women with allergies or contraindications to NSAIDs or lidocaine
* chronic pelvic pain of any etiology
* abnormalities in the cervix (such as fibrosis or isthmus-cervical incompetence)
* previous abortion with or without uterine curettage
* psychiatric disorders
* continued use of medications that could interfere with the pain threshold
C: Inclusion criteria:

* Nulliparous, as defined in this study as no history of pregnancy ≥ 24 weeks gestational age
* Desires insertion of either levonorgestrel-releasing IUD (LNG-IUD) or copper T380A IUD (Cu-IUD)
* No history of pregnancy in the last 6 weeks
* Able to provide written informed consent in English and comply with all study procedures

Exclusion criteria:

* Known allergy or hypersensitivity to lidocaine or other amino amide local anesthetics
* Prior failed IUD insertion
* Prior IUD use
* Use of narcotic or benzodiazepine medication within the last 24 hours
* U.S. Centers for Disease Control Medical Eligibility Criteria (MEC) category 3 or 4 classification for use of an IUD
* Positive pregnancy test or reasonable risk of pregnancy due to unprotected heterosexual intercourse since the last menstrual period
D: Inclusion Criteria:

1. plans for IUD insertion for contraception or abnormal uterine bleeding;
2. 18 to 49 years of age;
3. reached more than 6 weeks postpartum or 2 weeks postabortion if recently pregnant;
4. no prior IUD use;
5. not taken analgesics or anxiolytics in the previous 24 hours;
6. not taken misoprostol prior to IUD insertion;
7. the ability and are willing to give informed consent;
8. speaks English or Spanish.

Exclusion Criteria:

1. any contraindication to IUD placement;
2. allergy to lidocaine or sensitivities to components of the lidocaine or placebo gel;
3. chronic narcotic/benzodiazepine/barbiturate use within the past year.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Controlled Randomized Study of Protack, Securestrap and Glubran Glue as Fixation Devices in Laparoscopic Ventral Herniotomy
Brief Summary: Clinical, controlled, randomized, prospective study. Ventral hernias between 2(1.5)cm and 7 cm, laparoscopic surgery with intraperitoneal onlay mesh.

Three randomization groups of 25 patients giving a total of 75 patients. Mesh is fixated with either Protack, Securestrap or Glubran II. Primary outcome: postoperative pain on the 2nd postoperative day. Secondary outcomes: pain, quality of life, recurrence and adhesions at 1, 6, 12, 24, 36, 48 and 60 months postoperative.


Options:
A: Inclusion Criteria:

Patients will be eligible for enrollment into the study if they meet the following criteria: -Are 18 years of age or older -Have a diagnosis of ventral primary incisional hernia 9-225 cm2 in size. -Give informed consent for randomization - Have a negative pregnancy test. (Women)

Exclusion Criteria:

Patients will be excluded for the following reasons: -Hernia cannot be detected on physical examination - Primary ventral or umbilical hernia - Small hernia defined as less than 9 cm2 - Giant hernia defined as greater than 225 cm2 in size - ASA class 4 or 5, or contraindications to general anesthesia - Severe co morbid conditions likely to limit survival to less than 3 years - History of malignancy within the past 5 years except for non-melanoma skin cancer - Cirrhosis with or without ascites - Presence of bowel obstruction( partial or intermittent), strangulation, peritonitis, or perforation. - Presence of local or systemic infection - Participation in another clinical trial - Emergency operation - Prisoner
B: Inclusion Criteria:

* ventral hernia 2(1,5) \< dia \> 7 cm
* danish speaking
* of sound mind
* bmi \< 35
* ASA 3 or less, no contra indication against laparoscopy

Exclusion Criteria:

* other size hernias,
* no danish,
* bmi \> 35
C: Inclusion Criteria:

Table 1: Inclusion criteria Hernia site\*

* M2
* M3
* M4
* L2
* L3 Hernia width\*
* W1
* W2
* No previous vnetral/incisional hernia repair (R0)\*
* No incarcerated/strangulated hernia
* No contaminated field or bowel resection during repair
* BMI \< 35
* Age between 18 and 75 years old
* No severe COPD
* No autoimmune disease under corticosteroids treatment
* No cirrhosis Child B or C
* No uncontrolled diabetic (Glycated Hemoglobin \< 7)

  * According to: Muysoms FE, et al. Classification of primary and incisional abdominal wall hernias: Hernia 2009; 13: 407-414

Exclusion Criteria:

-
D: Inclusion Criteria:

* Non-acute incisional hernia of the abdominal wall or ventral hernia of the abdominal wall
* Informed consent
* Elective surgery

Exclusion Criteria:

* \< 18 years and \> 80 years
* Prednison \> 15 mg/24hr, started more than 2 weeks prior to surgery
* Chronical cough (severe COPD etc)
* Ascites
* Peritoneal dialysis
* Current abdominal infection
* Complete loss of abdominal domain due to hernia (diameter more than 10 cm?)
* Re-laparoscopic correction of ventral hernia

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Oral Paracetamol Versus Oral Ibuprofen Treatment
Brief Summary: The purpose of this study is to determine whether oral paracetamol or ibuprofen has a better or same efficacy and tolerance in closure of patent ductus arteriosus in preterm infants.


Options:
A: Inclusion Criteria:

* Inborn patients at JHS hospitals (admitted to the NICU at JMH within the first 72 hrs of age
* BW 500-1250 grams
* 23-32 wks gestational age
* \> 1d but \< 14d of age.

Exclusion Criteria:

* Major congenital malformations
* Proven sepsis (positive blood culture)
* Contraindications to the use of Ibuprofen or Indomethacin
* Terminal condition, not expected to survive beyond 48 h
* Infants born excessively SGA(3 S.D. below the mean for GA)
* Infants with initial PDA presentation that is hemodynamically significant
B: Inclusion Criteria:

* Birth weight below 1250 gram
* Diagnosed patent ductus arteriosus by Echocardiographic examination

Exclusion Criteria:

* Accompanied other congenital cardiac anomalies
* Urine output of less than 1 ml/kg/h during the preceding 8 h,
* Serum creatinine level \>1.6 mg/dl,
* Platelet count \<60,000/mm3,
* Liver failure,
* Hyperbilirubinemia requiring exchange transfusion
* Severe intracranial bleeding (Grade III - IV)
* Intestinal abnormality and necrotising enterocolitis
C: Inclusion Criteria:

* PDA diameter \> 1.5 mm and ductal (predominantly) left-to-right shunt
* Signed informed consent obtained from parent(s) or representative(s)
* Gestational age \< 28 completed weeks

Exclusion Criteria:

* Contraindication for administration of cyclooxygenase-inhibitors (COXi)
* Persistent pulmonary hypertension (ductal right-to-left shunt ≧33% of cardiac cycle)
* Congenital heart defect, other than PDA and/or patent foramen ovale (PFO)
* Life-threatening congenital defects
* Chromosomal abnormalities and/or congenital anomalies associated with abnormal neurodevelopmental outcome
* Use of COXi prior to randomization
D: Inclusion Criteria:

* a gestational age \< 32 weeks
* a birth weight \< 1500g
* a postnatal age between 48 and 96 hours, a respiratory distress requiring more than 25 % of oxygen supplementation
* an echocardiographic evidence of left to right significant shunting PDA

Exclusion Criteria:

* a right-to-left shunting
* major congenital anomalies
* IVH grade 3-4
* a tendency to bleed (defined by the presence of blood in the endotracheal aspirate, gastric aspirate, stools or urines and / or oozing from puncture sites)
* a serum creatinine level \>140µmol/l, a serum urea nitrogen \> 14 µmol/l and a platelet count \< 60000/mm3.

Answer: B